New Genomic Breast Cancer Test Now Available in the U.S.

Updated at: June 8, 2026 at 03:01 AM

A significant advancement in cancer care has arrived in the United States.

nounadvancement

As of June 8, 2026, Veracyte, Inc. has officially launched the Prosigna® Breast Risk of Recurrence (ROR) test.

nounVeracyte, Inc.

verblaunch

This genomic tool is designed for patients diagnosed with early-stage, hormone-receptor-positive (HR+) breast cancer, representing a major shift toward personalized medicine.

adjectivegenomic

nounpatient

adjectivepersonalize

By applying the PAM50 genomic classifier, the test generates a comprehensive risk score.

adjectivegenomic

This data helps oncologists determine the likelihood of cancer recurrence over a decade, guiding crucial decisions on whether a patient truly needs chemotherapy or can safely rely on endocrine therapy alone.

nounoncologist

nounchemotherapy

With over 225,000 such cases diagnosed annually in the U.S., this technology is set to improve quality of life by sparing many patients from unnecessary, harsh treatments.

adverbannually

nounpatient

Backed by recent clinical trials like the OPTIMA study, this launch marks a new era in tailoring cancer treatments to individual biological needs.

nounclinical trial

🎉

End of article

You read 7 focus sentences.

Challenge Mode

Comprehension Questions

What is the primary purpose of the Prosigna test?

To estimate the 10-year probability of breast cancer recurrence to guide treatment decisions.

To identify inherited mutations like BRCA1/2.

To screen the general population for early signs of cancer.

Reveal Answer

✓

Correct Choice

To estimate the 10-year probability of breast cancer recurrence to guide treatment decisions.

What type of technology does the Prosigna test utilize?

Blood-based protein analysis.

Ultrasound imaging.

Whole-transcriptome next-generation sequencing.

Reveal Answer

✓

Correct Choice

Whole-transcriptome next-generation sequencing.

How is the Prosigna test different from genetic testing?

It analyzes the genes within an existing tumor rather than checking for inherited mutations.

It is faster and cheaper than genetic testing.

It is used exclusively for patients with advanced-stage cancer.

Reveal Answer

✓

Correct Choice

It analyzes the genes within an existing tumor rather than checking for inherited mutations.

Which tumor classifier is uniquely used by the Prosigna test?

The HER2-positive screening model.

The OPTIMA diagnostic scale.

The PAM50 genomic classifier.

Reveal Answer

✓

Correct Choice

The PAM50 genomic classifier.

What is a potential benefit of using the Prosigna test for patients?

It automatically cures early-stage breast cancer.

It may spare patients from unnecessary chemotherapy and its side effects.

It replaces the need for any kind of cancer treatment.

Reveal Answer

✓

Correct Choice

It may spare patients from unnecessary chemotherapy and its side effects.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play